Search hospitals > Kansas > Pittsburg
Freeman Physician Group of Pittsburg
Claim this profilePittsburg, Kansas 66762
Conducts research for Cancer
Conducts research for Adenocarcinoma
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Lung Cancer
Conducts research for Breast Cancer
15 reported clinical trials
9 medical researchers
Summary
Freeman Physician Group of Pittsburg is a medical facility located in Pittsburg, Kansas. This center is recognized for care of Cancer, Adenocarcinoma, Non-Small Cell Lung Cancer, Lung Cancer, Breast Cancer and other specialties. Freeman Physician Group of Pittsburg is involved with conducting 15 clinical trials across 156 conditions. There are 9 research doctors associated with this hospital, such as Gary C. Doolittle, Chao H. Huang, Andrea D. Jewell, and Anup K. Kasi Loknath Kumar.Area of expertise
1Cancer
Stage IV
HER2 positive
ER positive
2Adenocarcinoma
Stage IV
Stage II
PD-L1 positive
Top PIs
Gary C. DoolittleHaysMed University of Kansas Health System3 years of reported clinical research
Studies Cancer
Studies Melanoma
18 reported clinical trials
29 drugs studied
Chao H. HuangUniversity of Kansas Health System Saint Francis Campus5 years of reported clinical research
Expert in Non-Small Cell Lung Cancer
Expert in Lung Cancer
19 reported clinical trials
31 drugs studied
Andrea D. JewellUniversity of Kansas Cancer Center4 years of reported clinical research
Studies Ovarian Cancer
Studies Fallopian Tube Cancer
16 reported clinical trials
38 drugs studied
Anup K. Kasi Loknath KumarUniversity of Kansas Cancer Center4 years of reported clinical research
Studies Adenocarcinoma
Studies Cancer
10 reported clinical trials
26 drugs studied
Clinical Trials running at Freeman Physician Group of Pittsburg
Breast Cancer
Bladder Carcinoma
Bladder Cancer
Lung Cancer
Renal Cell Carcinoma
Non-Small Cell Lung Cancer
Gastroesophageal Junction Adenocarcinoma
Gastric Cancer
Pancreatic Carcinoma
Ovarian Cancer
Chemotherapy + Hormone Therapy
for Breast Cancer
This trial is testing if adding additional cancer-fighting drugs to treatments that stop certain body functions is better than just using the treatments that stop those functions alone. It targets younger women with early-stage breast cancer who have a higher risk of dying from the disease. The treatment works by stopping certain body functions and using drugs to kill cancer cells.
Recruiting2 awards Phase 319 criteria
Cognitive Training
for Breast Cancer Survivors
This Phase III trial will examine the efficacy of computerized cognitive training methods on perceived cognitive impairment in breast cancer survivors.
Recruiting1 award N/A5 criteria
T-DM1 + Tucatinib
for Breast Cancer
This phase III trial studies how well trastuzumab emtansine (T-DM1) and tucatinib work in preventing breast cancer from coming back (relapsing) in patients with high risk, HER2 positive breast cancer. T-DM1 is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug, called DM1. Trastuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors, and delivers DM1 to kill them. Tucatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving T-DM1 and tucatinib may work better in preventing breast cancer from relapsing in patients with HER2 positive breast cancer compared to T-DM1 alone.
Recruiting1 award Phase 313 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Freeman Physician Group of Pittsburg?
Freeman Physician Group of Pittsburg is a medical facility located in Pittsburg, Kansas. This center is recognized for care of Cancer, Adenocarcinoma, Non-Small Cell Lung Cancer, Lung Cancer, Breast Cancer and other specialties. Freeman Physician Group of Pittsburg is involved with conducting 15 clinical trials across 156 conditions. There are 9 research doctors associated with this hospital, such as Gary C. Doolittle, Chao H. Huang, Andrea D. Jewell, and Anup K. Kasi Loknath Kumar.